"The on-schedule enrollment of the final patients in our phase 3 ENSURE trials of vidofludimus calcium marks another significant milestone for our late-stage MS program, bringing us meaningfully ...

Market Report forecasts growth across 7 major markets, reaching $25.9 billion by 2033 with a 1.7% CAGR. Driven by new DMTs and high-efficacy treatments, the market faces brand erosion from biosimilars ...

The company has late stage MS trials, which an independent analysis has already validated their design, and compelling phase 2 data suggest real pharmacological activity .

Jeffrey Huang, an associate professor of biology whose research focuses on multiple sclerosis (MS) treatment, said his team has identified a novel drug that reverses the effects of late-stage MS in ...

"The on-schedule enrollment of the final patients in our phase 3 ENSURE trials of vidofludimus calcium marks another significant milestone for our late-stage MS program, bringing us meaningfully ...

– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER ...

Immunic, Inc. Jun 05, 2025, 6:30 AM ET – Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – ...

Immunic, Inc. Jun 05, 2025, 6:30 AM ET – Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – ...